**Supplementary Appendix**

**Table A.1.** Search strategy for each database

| PubMed | (prophylactic OR "low-dose" OR "100 mg" OR "low-dosage" OR preventive OR prophylaxis) AND (Aspirin OR "salicylic acid" OR "acetylsalicylic acid") AND (elderly OR geriatric OR senile OR elder) AND (anemia OR anaemia OR iron OR ferritin OR hemoglobin OR "non-major bleeding" ) |
| --- | --- |
| Embase | (prophylactic OR 'low-dose' OR '100 mg' OR 'low-dosage' OR preventive OR prophylaxis) AND (aspirin OR 'salicylic acid' OR 'acetylsalicylic acid') AND (elderly OR geriatric OR senile OR elder) AND (anemia OR anaemia OR iron OR ferritin OR hemoglobin OR 'non-major bleeding') |
| Cochrane | (prophylactic OR 'low-dose' OR '100 mg' OR 'low-dosage' OR preventive OR prophylaxis) AND (aspirin OR 'salicylic acid' OR 'acetylsalicylic acid') AND (elderly OR geriatric OR senile OR elder) AND (anemia OR anaemia OR iron OR ferritin OR hemoglobin OR 'non-major bleeding') |


**Table A.2.** Risk of bias summary for randomized studies (RoB 2)

| **Study** | **Bias from randomization process** | **Bias due to deviations from intended interventions** | **Bias due to missing outcome data** | **Bias in measurement of the outcomes** | **Bias in selection of the reported result** | **Overall risk of bias** |
| --- | --- | --- | --- | --- | --- | --- |
| Silagy 1993 | Low | Low | Low | Low | Low | Low |
| Nelson 2008 | Low | Low | Low | Low | Low | Low |
| McQuilten 2023 | Low | Low | Low | Low | Low | Low |


**Table A.3.** Risk of bias summary for non-randomized studies (ROBINS-I)

| **Study** | **Bias due to confounding** | **Bias in selection of participants** | **Bias in classification of interventions** | **Bias due to deviations from intended interventions** | **Bias due to missing data** | **Bias in measurement of outcomes** | **Bias in selection of the reported result** | **Overall risk of bias judgment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Al-Azzam 2009 | Moderate | Serious | Low | Moderate | Low | Low | Low | Serious |
| Hammerman-Rozenberg 2006 | Moderate | Moderate | Low | Moderate | Low | Low | Low | Moderate |
| Kaffes 2003 | Moderate | Moderate | Low | Low | Low | Low | Low | Moderate |
| Nesher 2004 | Serious | Moderate | Low | Low | Moderate | Low | Low | Serious |


**Figure A.1.**  PRISMA flow diagram of study selection.




**Figure A.2.** Differences in MCH between aspirin users and non-aspirin users.




**Figure A.3.** Differences in MCV between aspirin users and non-aspirin users.




**Figure A.4.** Hemoglobin concentration between aspirin users and non-aspirin users.




**Figure A.5.** Subgroup analysis: hemoglobin concentration between aspirin users and non-aspirin users in RCT studies.





**Figure A.6.** Leave-one-out evaluation of anemia events.




**Figure A.7.** Leave-one-out evaluation of hemoglobin concentration.

****


**Figure A.8.** A. Baujat plot of anemia. B. Baujat plot of hemoglobin concentration.




**Figure A.9.** Funnel plot of hemoglobin concentration.




**Figure A.10.** Meta-regression of anemia outcome by proportion of female participants




**Figure A.11.** Meta-regression of anemia outcome by proportion of year of publication




**Figure A.12.** Meta-regression of anemia outcome by proportion of mean age of patients


**Figure A.13.** Meta-regression of hemoglobin difference outcome by proportion of mean age of patients




**Figure A.14.** Meta-regression of hemoglobin difference outcome by proportion of female sex




**Figure A.15.** Meta-regression of hemoglobin difference outcome by proportion of follow-up time



**Figure A.16.** Meta-regression of hemoglobin difference outcome by proportion of year of publication



**Figure A.17.** Trend in hemoglobin levels over time

****